Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0021 | 0 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0021 | 0 | 0.5 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0021 | 0 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0021 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0021 | 0 | 0.5 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0021 | 0 | 0.5 |
Loa Loa (eye worm) | mucolipin 1 | 0.0073 | 1 | 1 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0021 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0021 | 0 | 0.5 |
Schistosoma mansoni | mucolipin | 0.0073 | 1 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0021 | 0 | 0.5 |
Echinococcus multilocularis | mucolipin 3 | 0.0073 | 1 | 1 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0021 | 0 | 0.5 |
Echinococcus granulosus | mucolipin 3 | 0.0073 | 1 | 1 |
Schistosoma mansoni | mucolipin | 0.0067 | 0.8825 | 0.8825 |
Toxoplasma gondii | exonuclease III APE | 0.0021 | 0 | 0.5 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0021 | 0 | 0.5 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0021 | 0 | 0.5 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0021 | 0 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0021 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = -2 % | DNDI: Inhibition of Human African Trypanosomiasis, SBRI 427, in vitro at 2 ug.mL-1 | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.